CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial

Journal:
Nature Medicine
Published:
DOI:
10.1038/s41591-026-04362-1
Affiliations:
15
Authors:
28
Go to article
Institutions Authors Share
Vor Biopharma, United States of America (USA)
13.000000
13.000000
 0.46
HematoLogics Inc., United States of America (USA)
2.000000
 0.07
Washington University in St. Louis (WUSTL), United States of America (USA)
1.000000
 0.04
Baptist Health South Florida, United States of America (USA)
1.000000
 0.04
NIH NCI Center for Cancer Research (CCR), United States of America (USA)
1.000000
 0.04
Hôpital Maisonneuve-Rosemont (HMR), Canada
1.000000
 0.04
Hackensack University Medical Center (Hackensack UMC), United States of America (USA)
1.000000
 0.04
Moores Cancer Center, United States of America (USA)
1.000000
 0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
 0.04
KU Cancer Center, United States of America (USA)
1.000000
 0.04
University of Minnesota (UMN), United States of America (USA)
1.000000
 0.04
The Winship Cancer Institute of Emory University, United States of America (USA)
1.000000
 0.04
Stanford University, United States of America (USA)
1.000000
 0.04
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)
1.000000
 0.04
UH Seidman Cancer Center, CWRU, United States of America (USA)
1.000000
 0.04
Interested in Oncology and Carcinogenesis?